- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05115760
Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy
Intervention With Pea Protein Oral Nutrition Supplement Meal Replacement to Reduce Therapeutic Gastrostomy Tube Rates in Patients With Head and Neck Cancer Undergoing Chemoradiation Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the therapeutic G-tube placement rate during chemoradiation.
SECONDARY OBJECTIVES:
I. To determine percent weight change during and following treatment. II. To determine body mass index (BMI) changes during and following treatment. III. To determine changes in nutrition status based on Global Leadership Initiative on Malnutrition (GLIM) criteria IV. To determine lean body mass before and after treatment via psoas muscle surrogate measurement on routine staging scans.
V. To determine the adherence rate of Kate Farms oral nutritional replacement. VI. To determine changes in oral and gastrointestinal microbiota via 16s ribosomal ribonucleic acid (RNA) sequencing during and following treatment in an exploratory analysis.
VII. To determine changes in biomarkers during treatment. VIIa. Serum human papillomavirus (HPV) deoxyribonucleic (DNA). VIIb. 38-multiplex immune cytokine and chemokine panel in an exploratory analysis.
VIIc. Complete metabolic panel, complete blood count with differential, C-reactive protein (CRP).
VIId. Radiosensitivity germ-line biomarker panel. VIII. To determine physician-reported acute and late toxicities during and following treatment.
VIIIa. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. IX. To determine patient-reported quality of life during and following treatment.
IXa. University of Washington and Functional Assessment of Cancer Therapy questionnaires.
IXb. Functional Assessment of Cancer Therapy-Head & Neck (FACT-H&N). X. To determine clinical outcomes from treatment. Xa. Local/Locoregional control. Xb. Distant metastasis-free survival. Xc. Overall survival.
OUTLINE:
Patients receive Kate Farms pea protein oral nutrition supplement orally (PO) during their mealtimes as directed by their clinical dietitian during and up to 1 month following chemoradiation in the absence of unacceptable toxicity.
After completion of study intervention, patients are followed up for a minimum of 2 years.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vincent Basehart
- Phone Number: 310 267-8954
- Email: vbasehart@mednet.ucla.edu
Study Contact Backup
- Name: Jackie Hernandez
- Phone Number: 97624 310 206-8477
- Email: jhernandez@mednet.ucla.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California at Los Angeles
-
Contact:
- Jackie Hernandez
- Phone Number: 97624 310-206-8477
- Email: jhernandez@mednet.ucla.edu
-
Principal Investigator:
- Jie Deng
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Documented locally advanced head and neck malignancies for which concurrent chemoradiation has been recommended for definitive or adjuvant treatment
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) <= 2
- Body mass index > 18kg/m^2
- No evidence of distant metastatic disease (M1 disease)
- No G-tube placement prior to initiation of chemoradiation
- Eligible to undergo concurrent chemotherapy as determined by treating oncologist
- If a woman is of childbearing potential, a negative urine pregnancy test must be documented prior to proceeding with chemoradiation. Women of childbearing potential must agree to use medically acceptable forms of adequate contraception (hormonal or barrier method of birth control; or abstinence) for the entire study period and for up to 4 weeks after study treatment
- While negative pregnancy would be verified by urine test routinely prior to chemo-radiation therapy, we do not ask for verification of a negative urine pregnancy test.
- Ability to understand and willingness to sign a written informed consent
- Able to tolerate the taste of the Kate Farms Standard 1.4 or Standard 1.0 oral nutritional supplement at the time of screening
- Able and willing to participate in the Swallow Preservation Program at the Speech Pathology Clinic
- No evidence of clinically significant swallowing dysfunction by history or physical exam at time of radiation oncology consultation
Exclusion Criteria:
- Patients who refuse to use Kate Farms oral nutritional meal replacement due to its taste or other patient preference reasons
- Patients with allergies to any of the ingredients contained in Kate Farms nutritional replacement
- Evidence of clinically significant swallowing dysfunction by history or physical exam at time of radiation oncology consultation
- Refusal to sign the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Supportive care (pea protein oral nutrition supplement)
Patients receive Kate Farms pea protein oral nutrition supplement PO during their mealtimes as directed by their clinical dietitian during and up to 1 month following chemoradiation in the absence of unacceptable toxicity.
|
Ancillary studies
Other Names:
Ancillary studies
Given Kate Farms pea protein oral nutrition supplement PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance rate
Time Frame: Up to 1 month post chemoradiation
|
Will calculate the compliance rate and the corresponding 95% exact confidence interval.
|
Up to 1 month post chemoradiation
|
Gastrostomy (G)-tube placement rate
Time Frame: Up to 1 month post chemoradiation
|
Will calculate the compliance rate and the corresponding 95% exact confidence interval.
The 95% exact confidence interval (CI) will be provided.
|
Up to 1 month post chemoradiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight change measurement
Time Frame: Up to 2 years
|
Weight data will be collected at each visit and summary descriptive statistics will be calculated at each time points.
Repeated measure analysis of variance (ANOVA) will be used to explore if there are any change in these parameters over time.
Treatment breaks will be recorded in days per study patient and summarized.
G-tube placement timing will be recorded for patients receiving G-tubes, and the duration of G-tube dependence will be recorded in days per study patient and summarized.
|
Up to 2 years
|
Body mass index change measurement (BMI)
Time Frame: Up to 2 years
|
BMI data will be collected at each visit and summary descriptive statistics will be calculated at each time points.
Repeated measure ANOVA will be used to explore if there are any change in these parameters over time.
Treatment breaks will be recorded in days per study patient and summarized.
G-tube placement timing will be recorded for patients receiving G-tubes, and the duration of G-tube dependence will be recorded in days per study patient and summarized.
|
Up to 2 years
|
Global Leadership Initiative on Malnutrition criteria
Time Frame: Up to 2 years
|
Will be collected at each visit and summary descriptive statistics will be calculated at each time points.
Repeated measure ANOVA will be used to explore if there are any change in these parameters over time.
Treatment breaks will be recorded in days per study patient and summarized.
G-tube placement timing will be recorded for patients receiving G-tubes, and the duration of G-tube dependence will be recorded in days per study patient and summarized.
|
Up to 2 years
|
Patient-reported quality of life (QOL): The University of Washington Quality of Life Questionnaire (UW-QOL).
Time Frame: Up to 2 years
|
Patient-reported QOL according to the University of Washington (UW-QOL) questionnaires will be summarized by descriptive statistics by visit time points. The University of Washington Quality of Life Questionnaire (UW-QOL) is a self-administered scale measuring health-related quality life specifically for head and neck cancer patients. It is scored from 0-100 with higher scores indicating a better quality of life. |
Up to 2 years
|
Patient-reported quality of life (QOL): The Functional Assessment of Cancer Therapy-Head & Neck (FACT-HN).
Time Frame: Up to 2 years
|
Patient-reported QOL according to the Functional Assessment of Cancer Therapy-Head & Neck (FACT-HN) questionnaires will be summarized by descriptive statistics by visit time points. Functional Assessment of Cancer Therapy-Head & Neck (FACT-HN) is a 12 item self-administered scale measuring health-related quality of life specifically for head and neck cancer patients. Response options form a Likert scale and a subscale score is computed by summing across all items, with higher scores reflecting better QOL. |
Up to 2 years
|
Local/locoregional control
Time Frame: Up to 2 years
|
Will be estimated using the Kaplan-Meier method.
|
Up to 2 years
|
Distant metastasis-free survival
Time Frame: Up to 2 years
|
Will be estimated using the Kaplan-Meier method.
|
Up to 2 years
|
Overall survival
Time Frame: Up to 2 years
|
Will be estimated using the Kaplan-Meier method.
|
Up to 2 years
|
Incidence of adverse events (AEs)
Time Frame: Up to 2 years
|
Toxicity will be graded using the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version (v) 4.0.
AEs and serious (S)AEs will be reported using a CTCAE v 4.0 terminology and severity.
|
Up to 2 years
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jie Deng, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-002182
- NCI-2021-03612 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Head and Neck Carcinoma
-
Emory UniversityAstex Pharmaceuticals, Inc.RecruitingHead and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...United States
-
Centre Jean PerrinGroupement Inter-Régional de Recherche Clinique et d'Innovation Auvergne...RecruitingLocally Advanced Head and Neck CarcinomaFrance
-
University of Erlangen-Nürnberg Medical SchoolCompletedLocally Advanced Head and Neck Squamous Cell CarcinomaGermany
-
Second Affiliated Hospital, School of Medicine,...RecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaChina
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLocally Advanced Head and Neck Squamous Cell CarcinomaUnited States
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
NanobiotixRecruitingAged | Locally Advanced Head and Neck Squamous Cell CarcinomaFrance, Spain, Israel, United States, Taiwan, Finland, Japan, Belgium, Korea, Republic of, Hungary, China, Georgia, Portugal, Austria, Bulgaria, Canada, Czechia, Germany, Greece, Romania, Serbia
-
China Medical University HospitalCompletedLocally Advanced Head and Neck Carcinoma
-
AstraZenecaRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaSpain, United States, Italy, Korea, Republic of, United Kingdom, Vietnam, France, Japan, Brazil, India, Thailand, Germany, Canada, Turkey, Malaysia, Taiwan, Belgium, Austria, Hungary
-
Tianjin Medical University General HospitalTianjin Medical University Cancer Institute and HospitalNot yet recruitingLocally Advanced Head and Neck Squamous Cell CarcinomaChina
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States